Manuel Asensio.com - Life and professional experiences of investor advocate Manuel Asensio.

The Asensio Legacy

History

From 1993-2003, Manuel P. Asensio served as the Chairman, President and Chief Executive and Investment Officer of Asensio & Company, Inc. ("Asensio"). Manuel Asensio’s interest in financial markets began during his undergraduate years at the University of Pennsylvania. Upon completing his degree, Mr. Asensio continued his studies at the Harvard Business School. His first class educational pedigree and the many years he has worked in the securities industry make him an authority on investment research and the price discovery process. To demonstrate Mr. Manuel Asensio’s continuing level of professional excellence, he recently scored 90% on a Series 7 exam.

Asensio's Short Selling Research Methodology

Manuel Asensio conducts a preliminary analysis of public companies when it believes that a company's stock is trading at a price that is wholly unjustified when compared to its peers and/or its own future prospects. Manuel Asensio's preliminary analysis candidates come from its following the activities of known fraudulent stock promoters and industry sources. These sources include medical researchers, executives of companies in the subject company's industry and financial experts with extensive research experiences, which are either well known to Asensio or investigated to confirm their experience and knowledge with the subject matter.

The Winstar Story

On February 27, 2001 Winstar Communications, Inc. announced strong fourth quarter results. Winstar’s highly favorable announcement, and unanimous congratulatory announcements by the seven major Wall Street firms that follow Winstar, caused Winstar’s stock to rise 18.5% to an intra-day high of $14 per share giving Winstar’s equity a $1.3 billion market capitalization.
Read more...

The Solv-Ex Story

Solv-Ex Corporation had been one of U.S. history's most persistent and successful fraudulent stock schemes when Asensio & Company, Inc. focused its research and investigative capacity on its managers and their alleged business plans. During its 17 years of activity from 1980 to 1997 Solv-Ex raised over $139 million through a sophisticated combination of unregistered offerings and fraudulent claims. At its high Solv-Ex had a market value of over $440 Million. It also had enough cash to hire lawyers and private investigators in an attempt to intimidate its detractors and finance a public relations campaign that included ads in The Wall Street Journal promoting its corporate image. Asensio & Company was the target of most of Solv-Ex's attempts to discredit its opponents. In total Asensio & Company published 27 Solv-Ex research reports detailing management's fraudulent activities. On July 14, 1997 Solv-Ex's stock was halted for 65 days. On September 17, 1997 Solv-Ex was delisted.

The Hemispherx Story

Hemispherx is a 34-year-old alleged drug company that has never filed a New Drug Application ("NDA") with the FDA or completed a Phase III trial, despite claiming potential efficacy based on pre-clinical and Phase II testing in many different diseases including CFS, hepatitis, cancer and HIV. Simultaneously with failing to file an NDA, Hemispherx has used irregular and non-reproducible medical studies, authored by individuals with ties to Hemispherx, to perpetuate the fraudulent promotion of a 30-year-old drug it calls Ampligen. Ampligen is a 1970s substance once studied, along with many other failed dRNAs, as a potential interferon inducer before interferon itself became available as a prescription drug.

Press quotes

“Manuel Asensio is on the warpath. One of the leading short sellers on Wall Street, he's on the phone calling lawyers, editors, public officials--anyone who will listen--to his complaint about VeriSign... The issue is pretty obscure and Asensio is a stock trader, not a bureaucrat, so why does he care? He has a short position.”

Dan Ackman Forbes.com

Press quotes

Related Links